Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANI PHARMACEUTICALS INC Director's Dealing 2018

Mar 14, 2018

31676_dirs_2018-03-14_9492eba9-dd23-43f7-b818-b62baa75eede.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANI PHARMACEUTICALS INC (ANIP)
CIK: 0001023024
Period of Report: 2018-03-12

Reporting Person: RAYNOR DANIEL (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-03-12 Common Stock S 7928 $62.88 Disposed 316254 Indirect
2018-03-13 Common Stock S 14000 $61.81 Disposed 302254 Indirect
2018-03-13 Common Stock S 4117 $62.59 Disposed 298137 Indirect
2018-03-14 Common Stock S 1919 $62.02 Disposed 296218 Indirect

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $62.8223 to $63.037. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1)

F3: This transaction was executed in multiple trades at prices ranging from $61.51 to $62.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $62.50 to $63.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.